The 340B landscape continues to evolve. Regulatory and operational changes are making program management and administration more complex. Implementation of the IRA Maximum Fair Pricing (MFP) and upcoming HRSA 340B Rebate Model Pilot Program are creating an even more complicated future for covered entities.
Under the 340B Drug Pricing Program, covered entities and their designated child sites are eligible to access discounted medications, helping expand care for vulnerable populations such as low-income patients, children, and older adults. Examples of covered entities include federally qualified health centers, children’s hospitals, cancer hospitals, rural care centers, sole community hospitals, and specialized clinics (HRSA). As covered entities face increasing pressure to balance compliance, operational efficiency, and financial performance, the need for a more connected approach to 340B program management has never been greater.
Shields Health Solutions, which integrates specialty care operations across nearly 80 health systems nationwide, saw the market need for a truly connected infrastructure built to streamline 340B compliance, operational efficiency, and performance. With data, workflows, and human expertise connected in one environment, Shields 340B IQ™ addresses the growing 340B challenges while reducing manual burden and uncovering opportunities to improve financial and operational performance.
Where 340B Complexity Creates Operational Pressure
Managing a 340B drug pricing program requires strict oversight to ensure covered entities stay in bounds with regulatory compliance. But compliance only represents one piece of the overall operational puzzle. Program shifts leave covered entities to navigate a web of interconnected challenges to protect program integrity and performance. These challenges include:
- Keeping pace with evolving regulations and manufacturer policies: Changing federal requirements, state-level rules, manufacturer policies, and emerging models like the 340B Rebate Pilot mean covered entities must continuously adapt.
- Maintaining accurate patient and transaction eligibility: Reliable processes need to be in place to confirm 340B eligibility and prevent diversion across care and dispensing environments.
- Preventing duplicate discounts: Covered entities are responsible for ensuring manufacturers are not subject to a 340B discount and a Medicaid or other prohibited duplicate discount on the same drug transaction.
- Managing fragmented data and reconciliation workflows: Claims, purchasing, dispensing, and billing data often live in separate systems. This disconnection makes reconciliation and ongoing oversight difficult to do without connected workflows.
- Upholding continuous compliance and audit readiness: Covered entities must have accurate records, consistent controls, and clear visibility into program activity to effectively demonstrate compliance and respond to audits.
The 340B Rebate Model Raises the Operational Stakes
The 340B Rebate Model Pilot Program is set to kick off on January 1, 2027, introducing more operational consideration for covered entities. Shifting 340B savings on select drugs from an upfront discount at the point of purchase to a post-dispensing rebate creates new requirements around claims data submission, tracking, reconciliation, and oversight.
For covered entities already managing 340B workflows, the rebate pilot reinforces the need for integrated technology, reliable processes, and visibility in order to manage performance and protect savings.
Technology Built for a More Connected Approach to 340B
The complexity around 340B program management will only increase as regulatory audits intensify and financial models shift. To stay ahead, Shields built 340B IQ, a centralized command center with workflows that integrate with a health system’s environment and connect with Shields’ integrated specialty care model.
Available to Shields Health System partners, 340B IQ helps manage the interconnected financial, compliance, and operational demands that come with running an effective 340B program. It brings data, automation, analytics, and human oversight together allowing covered entities to move away from the fragmented, manual processes they are up against now.
By replacing fragmented, Excel-based approaches with real-time reporting and analytics, covered entities can identify previously missed savings opportunities and better understand financial performance.
Connected data and workflows help covered entities swiftly adapt to the changing 340B landscape. The upcoming Rebate Model Pilot is a prime example as 340B IQ securely integrates data from the Medicare Transaction Facilitator to validate MFP eligibility, verify manufacturer 340B reason codes, and compare expected refunds and rebates against actual payments.
The need is clear: Covered entities must have strong infrastructure that actively reduces manual burden, saves time, and identifies opportunities for growth. 340B IQ allows providers to evaluate high volumes of claims within minutes rather than hours or days. It automates auditing across claims while identifying and prioritizing compliance risks, keeping audit trails comprehensive and program integrity intact.
Shields’ approach ensures that the same focus on automation, visibility, and program performance extends to any emerging demands, now and in the future.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
